{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:00:18Z","timestamp":1790874018830,"version":"4.1.0"},"reference-count":195,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We present the updated British Association for Sexual Health and HIV (BASHH) guidelines for post\u2010exposure prophylaxis (PEP) to HIV following sexual exposures, occupational exposures and other nonoccupational exposures in the community. This serves as an update to the 2015 BASHH guideline on PEP following sexual exposures and the 2008 Expert Advisory Group on AIDS guidelines on HIV PEP. We aim to provide evidence\u2010based guidance on best clinical practice in the provision, monitoring and support of PEP for the prevention of HIV acquisition following sexual, occupational and other nonoccupational exposures in the community. The guideline covers when to prescribe PEP, what antiretroviral agents to use and how to manage PEP. This includes (i) evidence of PEP efficacy; (ii) evidence relating to individual\u2010level efficacy of antiretroviral therapy to prevent the sexual transmission of HIV; (iii) data on the detectable (transmissible) prevalence of HIV in specific populations; (iv) risk of HIV transmission following different types of sexual and occupational exposure; (v) baseline risk assessment; (vi) drug regimens and dosing schedules; (vii) monitoring PEP; (viii) baseline and follow\u2010up blood\u2010borne virus testing; (ix) the role of PEP within broader HIV prevention strategies, for example, HIV pre\u2010exposure prophylaxis (PrEP). The guideline also covers special scenarios such as PEP in pregnancy, breastfeeding and chronic hepatitis B virus infection, and when PEP should be considered in people using HIV PrEP. The guidelines are aimed at clinical professionals directly involved in PEP provision and other stakeholders in the field. A proforma to assist PEP consultations is included. A public consultation process was undertaken prior to finalizing the recommendations.<\/jats:p>","DOI":"10.1111\/hiv.13208","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T02:00:14Z","timestamp":1644890414000},"page":"494-545","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["UK guideline for the use of HIV post\u2010exposure prophylaxis\u00a02021"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5070-532X","authenticated-orcid":false,"given":"Fiona","family":"Cresswell","sequence":"first","affiliation":[{"name":"Global Health and Infection Brighton and Sussex Medical School  Brighton UK"},{"name":"Clinical Research Department London School of Hygiene and Tropical Medicine  UK"},{"name":"Brighton and Sussex University Hospitals NHS Trust  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Asanati","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, School of Public Health Imperial College  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Bhagani","sequence":"additional","affiliation":[{"name":"Royal Free Hospital  London UK"},{"name":"Institute for Global Health University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital  London UK"},{"name":"Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-8109","authenticated-orcid":false,"given":"Valerie","family":"Delpech","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Public Health England  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-9144","authenticated-orcid":false,"given":"Jayne","family":"Ellis","sequence":"additional","affiliation":[{"name":"Global Health and Infection Brighton and Sussex Medical School  Brighton UK"},{"name":"University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[{"name":"HIV Medicine and Clinical Trials Guy\u2019s and St Thomas\u2019 Hospital  London UK"},{"name":"Kings College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Furness","sequence":"additional","affiliation":[{"name":"Cardiff Royal Infirmary  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Kingston","sequence":"additional","affiliation":[{"name":"British Association of Sexual Health and HIV Clinical Effectiveness Group  Macclesfield UK"},{"name":"Manchester Royal Infirmary  Manchester UK"},{"name":"Manchester University  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Mansouri","sequence":"additional","affiliation":[{"name":"Occupational Health School of Medicine Cardiff University  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Samarawickrama","sequence":"additional","affiliation":[{"name":"Sexual Health South West London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kat","family":"Smithson","sequence":"additional","affiliation":[{"name":"National AIDS Trust  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sparrowhawk","sequence":"additional","affiliation":[{"name":"Terrence Higgins Trust  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-7501","authenticated-orcid":false,"given":"Paul","family":"Rafferty","sequence":"additional","affiliation":[{"name":"Belfast Health and Social Care Trust  Belfast UK"},{"name":"HIV Pharmacy Association Representative  Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Roper","sequence":"additional","affiliation":[{"name":"Mortimer Market Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-1775","authenticated-orcid":false,"given":"Laura","family":"Waters","sequence":"additional","affiliation":[{"name":"Mortimer Market Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8817-4651","authenticated-orcid":false,"given":"Alison","family":"Rodger","sequence":"additional","affiliation":[{"name":"Royal Free Hospital  London UK"},{"name":"Institute for Global Health University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-9274","authenticated-orcid":false,"given":"Nadi","family":"Gupta","sequence":"additional","affiliation":[{"name":"British HIV Association Guideline Committee  London UK"},{"name":"Rotherham NHS Foundation Trust  Rotherham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"e_1_2_22_2_1","unstructured":"Expert Advisory Group on AIDS.Change to recommended regimen for post\u2010exposure prophylaxis (PEP) 2015. Available from:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/351633\/Change_to_recommended_regimen_for_PEP_starter_pack_final.pdf"},{"key":"e_1_2_22_3_1","unstructured":"British Association for Sexual Health and HIV CEG.Framework for Guideline Development and Assessment 2014. Available from:http:\/\/www.bashh.org\/documents\/GUIDELINES%20FRAMEWORK%20April%202015.pdf"},{"key":"e_1_2_22_4_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.171011"},{"key":"e_1_2_22_5_1","unstructured":"Centre for Disease Control.Antiretroviral psotexposure prophylaxis after sexual injection\u2010drug use or other nonoccupational exposure to HIV in the United States Morbity and Mortality Weekly Reports 2005\/54(RR02);1\u2010202005. Available from:http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5402a1.htm"},{"key":"e_1_2_22_6_1","unstructured":"World Health Organisation.Guidelines on post\u2010exposure prophylaxis for HIV and the use of co\u2010trimoxazole prophylaxis for HIV\u2010related infections among adults adolescents and children.2014."},{"key":"e_1_2_22_7_1","unstructured":"Australian Society for HIV Medicine.National guidelines for post\u2010exposure prophylaxis after non\u2010occupational and occupational exposure to HIV 2013. Available from:http:\/\/www.ashm.org.au\/Documents\/Guide\u2010for\u2010the\u2010Management\u2010of\u2010Occupational\u2010and\u2010Non\u2010Occupational\u2010Post\u2010Exposure\u2010Prophylaxis.pdf"},{"key":"e_1_2_22_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00056-9"},{"key":"e_1_2_22_9_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.215"},{"key":"e_1_2_22_10_1","unstructured":"HopeT VisualizingHIV.Visualizing HIV Transmission and Prevention. Conference on Retroviruses and Opportunisitic Infections Madrid 2018."},{"key":"e_1_2_22_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-78"},{"key":"e_1_2_22_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.5.4265-4273.1998"},{"key":"e_1_2_22_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.20.9771-9775.2000"},{"key":"e_1_2_22_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200008180-00029"},{"key":"e_1_2_22_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328321302d"},{"key":"e_1_2_22_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372101"},{"key":"e_1_2_22_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(01)90811-4"},{"key":"e_1_2_22_18_1","unstructured":"Public Health England.Eye of the Needle Report. Surveillance of significant occupational exposures to bloodborne viruses in healthcare workers in the United Kingdom \u2013 update on seroconversions 2020."},{"key":"e_1_2_22_19_1","volume-title":"Eye of the Needle: United Kingdom Surveillance of Significant Occupational Exposures to bloodborne Viruses in Healthcare Workers","author":"Woode Owusu M","year":"2014"},{"issue":"10","key":"e_1_2_22_20_1","first-page":"E050310 2","article-title":"Occupationally acquired HIV: international reports to December 2002","volume":"10","author":"Tomkins S","year":"2005","journal-title":"Weekly Releases"},{"key":"e_1_2_22_21_1","doi-asserted-by":"publisher","DOI":"10.2807\/esm.04.03.00076-en"},{"key":"e_1_2_22_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit485"},{"key":"e_1_2_22_23_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta13140"},{"key":"e_1_2_22_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404150-00010"},{"key":"e_1_2_22_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-010-9712-1"},{"key":"e_1_2_22_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61127-7"},{"key":"e_1_2_22_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417743158"},{"key":"e_1_2_22_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ511"},{"key":"e_1_2_22_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx246"},{"key":"e_1_2_22_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw049"},{"key":"e_1_2_22_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001440"},{"key":"e_1_2_22_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2016-052806"},{"key":"e_1_2_22_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/497268"},{"key":"e_1_2_22_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2014.0017"},{"issue":"2","key":"e_1_2_22_35_1","first-page":"23","article-title":"Acute HIV infection after initiation of post\u2010exposure prophylaxis following sexual exposure: reasons, challenges and usggested managment","volume":"16","author":"Haidari GFS","year":"2015","journal-title":"HIV Med"},{"key":"e_1_2_22_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05005-9"},{"key":"e_1_2_22_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7283.397"},{"key":"e_1_2_22_38_1","doi-asserted-by":"publisher","DOI":"10.1086\/318829"},{"key":"e_1_2_22_39_1","first-page":"146","article-title":"The impact of the 2011 post\u2010exposure HIV prophylaxis following sexual exposure (PEPSE) guidelines: A regional retrospective audit across three genitourinary centres","volume":"15","author":"Bennett A","year":"2014","journal-title":"HIV Med"},{"key":"e_1_2_22_40_1","first-page":"131","article-title":"An audit of PEPSE in the West Midlands","volume":"15","author":"Spice B","year":"2014","journal-title":"HIV Med"},{"key":"e_1_2_22_41_1","first-page":"148","article-title":"Evaluation of PEPSE use in a district general hospital genitourinary medicine department","volume":"15","author":"Parkash V","year":"2014","journal-title":"HIV Med"},{"key":"e_1_2_22_42_1","first-page":"39","article-title":"A retrospective audit in a London HIV clinic, assessing the post\u2010exposure prophylaxis for HIV following sexual exposure (PEPSE)","volume":"15","author":"Awosusi F","year":"2014","journal-title":"HIV Med"},{"key":"e_1_2_22_43_1","first-page":"9","article-title":"Twenty\u2010eight days later: Audit of postexposure prophylaxis following sexual exposure (PEPSE) in a community sexual health clinic for men who have sex men","volume":"24","author":"Rowley D","year":"2013","journal-title":"Int J STD AIDS"},{"key":"e_1_2_22_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2012-050601c.18"},{"key":"e_1_2_22_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2005.017764"},{"key":"e_1_2_22_46_1","unstructured":"HIV Drug Resistance Database. Available from:http:\/\/www.hivrdb.org.uk\/hiv\u2010drug\u2010resistance\u2010uk"},{"key":"e_1_2_22_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12617"},{"key":"e_1_2_22_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.04.012"},{"key":"e_1_2_22_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200202150-00018"},{"key":"e_1_2_22_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600693"},{"key":"e_1_2_22_51_1","volume-title":"HIV Transmission Risk Through Condomless Sex If HIV+ Partner on Suppressive ART: PARTNER study","author":"Rodger ABT","year":"2014"},{"key":"e_1_2_22_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30132-2"},{"key":"e_1_2_22_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/156.1.189"},{"issue":"3","key":"e_1_2_22_54_1","first-page":"303","article-title":"Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984\u20131989","volume":"6","author":"Samuel MC","year":"1993","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_22_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010003"},{"issue":"3","key":"e_1_2_22_56_1","first-page":"S223","article-title":"HIV type 1 transmission probabilities: estimates from epidemiological studies","volume":"14","author":"Mastro TD","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"e_1_2_22_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704103361507"},{"key":"e_1_2_22_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq057"},{"key":"e_1_2_22_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(89)90098-X"},{"key":"e_1_2_22_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283372d90"},{"key":"e_1_2_22_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408113310601"},{"key":"e_1_2_22_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04331-2"},{"key":"e_1_2_22_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009564"},{"key":"e_1_2_22_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199604010-00010"},{"key":"e_1_2_22_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02460671"},{"issue":"1","key":"e_1_2_22_66_1","first-page":"1","article-title":"The cofactor effect of genital ulcers on the per\u2010exposure risk of HIV transmission in sub\u2010Saharan Africa","volume":"98","author":"Hayes RJ","year":"1995","journal-title":"J Trop Med Hyg"},{"key":"e_1_2_22_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03720010033036"},{"key":"e_1_2_22_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200206140-00017"},{"issue":"1","key":"e_1_2_22_69_1","first-page":"55","article-title":"Modeling HIV infectivity: must sex acts be counted?","volume":"3","author":"Kaplan EH","year":"1990","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_22_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410120035005"},{"key":"e_1_2_22_71_1","first-page":"929","article-title":"Case\u2010control study of HIV seroconversion in healthcare workers after percutaneous exposure to HIV\u2010infected blood France, United Kingdom and United States, January 1988\u2013August 1994","volume":"44","author":"Centres for Disease Control","year":"1995","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_22_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89441-7"},{"issue":"4","key":"e_1_2_22_73_1","first-page":"402","article-title":"The potential for transmission of human immunodeficiency virus through human bites","volume":"6","author":"Richman KM","year":"1993","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_22_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90209-6"},{"key":"e_1_2_22_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12625"},{"key":"e_1_2_22_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir751"},{"key":"e_1_2_22_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199816000-00004"},{"key":"e_1_2_22_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200110000-00005"},{"key":"e_1_2_22_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy113"},{"key":"e_1_2_22_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00011"},{"key":"e_1_2_22_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833f9f43"},{"key":"e_1_2_22_82_1","doi-asserted-by":"publisher","DOI":"10.1086\/338231"},{"key":"e_1_2_22_83_1","unstructured":"Public Health England.Guidance on management of potential exposure to blood\u2010borne viruses in emergency workers 2019."},{"key":"e_1_2_22_84_1","doi-asserted-by":"publisher","DOI":"10.1086\/503164"},{"key":"e_1_2_22_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000218543.46963.6d"},{"issue":"5","key":"e_1_2_22_86_1","first-page":"472","article-title":"Management of health care workers following occupational exposure to hepatitis B, hepatitis C, and human immunodeficiency virus","volume":"22","author":"Sin WW","year":"2016","journal-title":"Hong Kong Med J"},{"key":"e_1_2_22_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2017.03.012"},{"key":"e_1_2_22_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2014.03.001"},{"issue":"5","key":"e_1_2_22_89_1","first-page":"61","article-title":"The management of needlestick injuries","volume":"110","author":"Himmelreich H","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_22_90_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-142"},{"key":"e_1_2_22_91_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462419844852"},{"key":"e_1_2_22_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir654"},{"key":"e_1_2_22_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30375-3"},{"key":"e_1_2_22_94_1","unstructured":"Public Health England HPS Public Health Wales and Public Health Agency Northern Ireland.Unlinked Anonymous Monitoring (UAM) Survey of HIV and viral hepatitis among PWID.2019."},{"key":"e_1_2_22_95_1","unstructured":"NashS DesaiS CroxfordSet al.Progress towards ending the HIV epidemic in the United Kingdom: 2018 report. 2018 November 2018."},{"key":"e_1_2_22_96_1","unstructured":"Public Health England HPS Public Health Wales and Public Health Agency Northern Ireland.Shooting Up: Infections among people who inject drugs in the UK 2018.2019."},{"key":"e_1_2_22_97_1","volume-title":"HIV in the United Kingdom: Towards Zero 2030","author":"O\u2019Halloran C","year":"2019"},{"key":"e_1_2_22_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30036-0"},{"key":"e_1_2_22_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.02.002"},{"key":"e_1_2_22_100_1","volume-title":"Public Health Wales, and Public Health Agency Northern Ireland, Substance misuse services for men who have sex with men involved in chemsex","author":"Public Health England HPS","year":"2015"},{"key":"e_1_2_22_101_1","volume-title":"Sexualised Drug Use and Specialist Service Experience Among Men Who Have Sex With Men Attending Urban and Non\u2010Urban Sexual Health Clinics in England and Scotland: Results of the Drugs and Sex Survey","author":"Kennedy R","year":"2018"},{"key":"e_1_2_22_102_1","first-page":"956462417746897","article-title":"United Kingdom national guideline on the sexual health care of men who have sex with men","volume":"2018","author":"Clutterbuck D","year":"2016","journal-title":"Int J STD AIDS"},{"key":"e_1_2_22_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421303"},{"key":"e_1_2_22_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60705-2"},{"key":"e_1_2_22_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832b7dca"},{"key":"e_1_2_22_106_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5148"},{"key":"e_1_2_22_107_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200203010-00003"},{"key":"e_1_2_22_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12078"},{"key":"e_1_2_22_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-8080(03)02285-7"},{"key":"e_1_2_22_110_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002836"},{"key":"e_1_2_22_111_1","unstructured":"UNAIDS.The GAP report 2014.2014."},{"key":"e_1_2_22_112_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.055624"},{"key":"e_1_2_22_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199901010-00011"},{"key":"e_1_2_22_114_1","unstructured":"European AIDS Clinical Society.EACS Treatment Guidelines V7.1 2014. Available from:http:\/\/www.eacsociety.org\/guidelines\/eacs\u2010guidelines\/eacs\u2010guidelines.html"},{"key":"e_1_2_22_115_1","unstructured":"Department of Health and Human Services PoAGfAaA.Guidelines for the use of antitretoviral agents in HIV\u20101 infected adults and adolescents 2014. Available from:https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf"},{"key":"e_1_2_22_116_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32833a0b69"},{"key":"e_1_2_22_117_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_2_22_118_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_2_22_119_1","unstructured":"McCormackSDDeditor. Pragmatic Open\u2010Label Randomised Trial of Preexposure Prophylaxis: The PROUD study. Conference of Retroviruses and Opportunistic Infections; 2015 February 23\u201026 2015; Seattle."},{"key":"e_1_2_22_120_1","unstructured":"MolinaJMCC CharreauI MeyerL SpireB PialouxG et al. eds.On Demand PrEP With Oral TDF\u2010FTC in MSM: Results of the ANRS Ipergay Trial. Conference on retroviruses and opportuisitc infections; 2015 February 23\u2010262015; Seattle USA."},{"key":"e_1_2_22_121_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ069"},{"key":"e_1_2_22_122_1","unstructured":"RuanePCA PostFA SchembriG JessenH TrottierB.Phase 3 randomized controlled DISCOVER study of daily emtricitabine\/tenofovir alafenamide (F\/TAF) or emtricitabine\/tenofovir disoproxil fumarate (F\/TDF) for HIV pre\u2010exposure prophylaxis week 96 results. 17th European AIDS Conference; Basel2019."},{"key":"e_1_2_22_123_1","unstructured":"Electronic Medicines Compendium.Truvada SPC. Available from:https:\/\/www.medicines.org.uk\/emc\/product\/3890#UNDESIRABLE_EFFECTS"},{"key":"e_1_2_22_124_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074609"},{"key":"e_1_2_22_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir510"},{"key":"e_1_2_22_126_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1084"},{"key":"e_1_2_22_127_1","unstructured":"Electronic Medicines Compendium.Summary of medicinal product characterisitcs. Dolutegravir.2019. Available from:https:\/\/www.medicines.org.uk\/emc\/product\/10057\/smpc"},{"key":"e_1_2_22_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12938"},{"key":"e_1_2_22_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12075"},{"key":"e_1_2_22_130_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.15.6.18165"},{"key":"e_1_2_22_131_1","first-page":"4","article-title":"Raltegravir: Alternative postexposure prophylaxis regimen?","volume":"24","author":"Annandale D","year":"2013","journal-title":"Int J STD AIDS"},{"key":"e_1_2_22_132_1","unstructured":"LA LealL TorresB InciarteA LuceroC MallolasJ eds.Tenofovir\/Emtricitabine Plus LPV\/r vs MVC or Raltegravir for PEP: 2 Randomized Trials. Conference on Retroviruses and Opportunisitic Infections; 2015 23\u201026th Febraury2015; Seattle USA."},{"key":"e_1_2_22_133_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001447"},{"key":"e_1_2_22_134_1","first-page":"37","article-title":"Recreational drug use among genitourinary medicine attendees: implications for service delivery","volume":"24","author":"Scrivener J","year":"2013","journal-title":"Int J STD AIDS"},{"key":"e_1_2_22_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12363"},{"key":"e_1_2_22_136_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1955"},{"issue":"1","key":"e_1_2_22_137_1","first-page":"497","article-title":"Darunavir(DRV)\/r\u2010Based PEP versus standard of care (SOC) \u2013 the randomized PEPDar study","volume":"22","author":"Fatkenheuer G","year":"2014","journal-title":"Topics Antiviral Med"},{"key":"e_1_2_22_138_1","unstructured":"MilinkovicPB Arenas\u2010PintoA BrimaNet al.Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra\u00ae in combination with Truvada\u00ae for HIV post exposure prophylaxis (MiPEP Trial). European AIDS Clinical Society; Barcelona2015."},{"key":"e_1_2_22_139_1","doi-asserted-by":"publisher","DOI":"10.1086\/650697"},{"key":"e_1_2_22_140_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12127"},{"issue":"10","key":"e_1_2_22_141_1","first-page":"A1","article-title":"Domperidone: risks of cardiac side effects \u2013 indication restricted to nausea and vomiting, mew contraindications, and reduced dose and duration of use","volume":"7","author":"Medicines Health Regulatory Authority","year":"2014","journal-title":"Drug Safety Update"},{"key":"e_1_2_22_142_1","unstructured":"Electronic Medicines Compendium.Raltegravir Summary of Product Characteristics for Isentress. Available from:http:\/\/www.medicines.org.uk\/emc\/medicine\/20484\/SPC\/"},{"key":"e_1_2_22_143_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015149"},{"key":"e_1_2_22_144_1","unstructured":"Electronic Medicines Compendium.SPC raltegravir. Available from:https:\/\/www.medicines.org.uk\/emc\/medicine\/20484"},{"key":"e_1_2_22_145_1","unstructured":"University of Liverpool.HIV Drug Interactions. Available from:https:\/\/www.hiv\u2010druginteractions.org\/"},{"key":"e_1_2_22_146_1","first-page":"1","article-title":"Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys","author":"James B","year":"2014","journal-title":"Nature"},{"key":"e_1_2_22_147_1","unstructured":"Expert Advisory Group of AIDSHIV post\u2010exposure prophylaxis: guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS (2008) 2008. Available from:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/203139\/HIV_post\u2010exposure_prophylaxis.pdf"},{"key":"e_1_2_22_148_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ093"},{"key":"e_1_2_22_149_1","first-page":"124","article-title":"Does dropping day 5 PEP follow\u2010up affect other outcomes?","volume":"15","author":"O'Keeffe C","year":"2014","journal-title":"HIV Med"},{"key":"e_1_2_22_150_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00014"},{"key":"e_1_2_22_151_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200205240-00011"},{"key":"e_1_2_22_152_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824a03b8"},{"key":"e_1_2_22_153_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp446"},{"key":"e_1_2_22_154_1","unstructured":"Centers for Disease Control and Prevention.CDC Guidance for Evaluating Health\u2010Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR.2013;62."},{"key":"e_1_2_22_155_1","unstructured":"Gary BrookSB Ranjababu KulasegaramR TorkingtonA MutimerD HodgesE.United Kingdom National Guideline on the Management of the Viral 1 Hepatitides A B & C 2015 2015. Available from:http:\/\/www.bashh.org\/BASHH\/Guidelines\/Guidelines\/BASHH\/Guidelines\/Guidelines.aspx"},{"key":"e_1_2_22_156_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu782"},{"key":"e_1_2_22_157_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000151"},{"key":"e_1_2_22_158_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2013-051184.0598"},{"key":"e_1_2_22_159_1","doi-asserted-by":"publisher","DOI":"10.1071\/SH12190"},{"key":"e_1_2_22_160_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2010.484457"},{"key":"e_1_2_22_161_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403260-00010"},{"issue":"2","key":"e_1_2_22_162_1","first-page":"s2","article-title":"BHIVA\/BASHH guidelines on the use of HIV pre\u2010exposure prophylaxis (PrEP) 2018","volume":"20","author":"Brady M","year":"2019","journal-title":"HIV Med"},{"key":"e_1_2_22_163_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31828ece33"},{"key":"e_1_2_22_164_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000857"},{"key":"e_1_2_22_165_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0102-x"},{"key":"e_1_2_22_166_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001280"},{"key":"e_1_2_22_167_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13716"},{"key":"e_1_2_22_168_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14142"},{"key":"e_1_2_22_169_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15064"},{"key":"e_1_2_22_170_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807653"},{"key":"e_1_2_22_171_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905230"},{"key":"e_1_2_22_172_1","unstructured":"ZashR.Update on neural tube defects with antiretroviral therapy exposure in the Tsepamo study Botswana. AIDS 2020 Virtual; Virtual2020."},{"key":"e_1_2_22_173_1","unstructured":"al MMe.Periconceptional antiretroviral exposure and central nervous system (CNS) and neural tube birth defects \u2013 data from Antiretroviral Pregnancy Registry (APR). Intenrational AIDS Conference Mexico City 2019."},{"key":"e_1_2_22_174_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190320162507"},{"key":"e_1_2_22_175_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000022401.14710.c5"},{"key":"e_1_2_22_176_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv080"},{"key":"e_1_2_22_177_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002895"},{"key":"e_1_2_22_178_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001259"},{"key":"e_1_2_22_179_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001755"},{"key":"e_1_2_22_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"e_1_2_22_181_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004006"},{"key":"e_1_2_22_182_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273"},{"key":"e_1_2_22_183_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw077"},{"key":"e_1_2_22_184_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0182"},{"key":"e_1_2_22_185_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.358"},{"key":"e_1_2_22_186_1","unstructured":"Electronic Medicines Compendium.Truvada Summary of Product Characteristics 2015. Available from:https:\/\/www.medicines.org.uk\/emc\/medicine\/15826"},{"key":"e_1_2_22_187_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182829bd0"},{"key":"e_1_2_22_188_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000167155.44980.e8"},{"issue":"1","key":"e_1_2_22_189_1","first-page":"1","article-title":"British HIV Association guidelines for the treatment of HIV\u20101\u2010positive adults with antiretroviral therapy 2012","volume":"15","author":"Williams I","year":"2014","journal-title":"HIV Med"},{"key":"e_1_2_22_190_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043754"},{"key":"e_1_2_22_191_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000461"},{"key":"e_1_2_22_192_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12718"},{"key":"e_1_2_22_193_1","unstructured":"NHS England.Specialised Services Circular \u2010 Pre\u2010Exposure Prophylaxis (PrEP) to prevent HIV: clarification of commissioning position 2015. Available from:http:\/\/www.bashh.org\/documents\/SSC1516%20Position%20regarding%20PrEP%20April%202015.pdf"},{"key":"e_1_2_22_194_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2007.007216"},{"key":"e_1_2_22_195_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125018"},{"key":"e_1_2_22_196_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz068"}],"updated-by":[{"DOI":"10.1111\/hiv.13327","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000}}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13208","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13208","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T16:05:27Z","timestamp":1692979527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":195,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/hiv.13208"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13208","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1111\/hiv.13327","asserted-by":"object"}]},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"2021-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}